TABLE 1.
Protein | Expression in GC | Effects on autophagy | Chemotherapy | Effects on chemosensitivity | Downstream pathways | References |
WASF3 | NA | Inducing | OXA | Decreasing | ATG12 | Nie et al., 2020 |
PLK1 | Up | Inducing | DDP | Decreasing | CDC25C, cyclin B1, LC3-I, LC3-II | Chen et al., 2019 |
AQP3 | Up | Inducing | DDP | Decreasing | Atg5, Beclin-1, P62 | Dong et al., 2016 |
DJ-1 | Up | Inducing | EPI | Decreasing | LC3-I, LC3-II | Pan et al., 2018 |
TSPAN9 | Up | Inducing | 5-FU | Decreasing | PI3K/AKT/mTOR | Qi et al., 2020 |
CD133 | Up | Inducing | DDP | Decreasing | PI3K/AKT/mTOR | Lu et al., 2019 |
TRIM14 | Up | Inducing | 5-FU, OXA | Decreasing | AMPK/mTOR | Xiao et al., 2020 |
MTDH | Up | Inducing | 5-FU | Decreasing | AMPK/ATG5 | Pei et al., 2018 |
ERAS | Up | Inhibiting | DDP | Decreasing | AKT/mTOR | Tian et al., 2019 |
CCL2 | Up | Inhibiting | DDP | Decreasing | PI3K/AKT/mTOR, SQSTM1 | Xu et al., 2018b |
RAB5A | Up | Inhibiting | DDP | Decreasing | mTOR | Xu et al., 2018a |
MGMT | NA | Inhibiting | DDP | Increasing | ATG4B | Lei et al., 2020 |
CISD2 | Down | Inhibiting | 5-FU | Increasing | AKT/mTOR | Sun et al., 2017 |
5-FU, 5-fluorouracil; DDP, cisplatin; EPI, epirubicin; GC, gastric cancer; OXA, oxaliplatin; NA, not applicable.